QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
NASDAQ:IONS

Ionis Pharmaceuticals - IONS Stock Forecast, Price & News

$38.03
-0.95 (-2.44%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$37.99
▼
$38.90
50-Day Range
$38.76
▼
$46.52
52-Week Range
$28.25
▼
$48.82
Volume
1.23 million shs
Average Volume
1.06 million shs
Market Capitalization
$5.40 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.80

Ionis Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
23.1% Upside
$46.80 Price Target
Short Interest
Healthy
4.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
-3.58
Upright™ Environmental Score
News Sentiment
0.83mentions of Ionis Pharmaceuticals in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$20,493 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.31) to ($1.70) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

646th out of 1,023 stocks

Pharmaceutical Preparations Industry

316th out of 501 stocks

See Top Rated MarketRank™ Stocks Here
IONS stock logo

About Ionis Pharmaceuticals (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Receive IONS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IONS Stock News Headlines

December 6, 2022 | finance.yahoo.com
Biogen's (BIIB) ALS Drug Tofersen Filing Accepted in Europe
December 5, 2022 | markets.businessinsider.com
Ionis Announces EMA's Acceptance Of Marketing Authorization Application Of Tofersen For SOD1-ALS
December 5, 2022 | finance.yahoo.com
Ionis announces European Medicines Agency accepts Marketing Authorization Application of tofersen to treat rare, genetic form of ALS
November 30, 2022 | americanbankingnews.com
Brokerages Set Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Target Price at $46.80
November 23, 2022 | barrons.com
Premarket Movers: Autodesk, Ionis Pharmaceuticals, Deere
November 15, 2022 | finance.yahoo.com
Ionis (IONS) Inks Deal to Develop Precision Genetic Medicines
November 14, 2022 | finance.yahoo.com
How rooting around in the dirt landed an East Bay startup an $80M deal
November 11, 2022 | finance.yahoo.com
Should You Be Worried About Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) 1.2% Return On Equity?
November 10, 2022 | markets.businessinsider.com
4 Analysts Have This to Say About Ionis Pharmaceuticals
November 10, 2022 | finance.yahoo.com
Ionis (IONS) Q3 Earnings & Sales Beat Estimates, Stock Up
November 9, 2022 | seekingalpha.com
Ionis Pharmaceuticals, Inc. (IONS) Q3 2022 Earnings Call Transcript
November 9, 2022 | finance.yahoo.com
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates
November 9, 2022 | finance.yahoo.com
Ionis reports third quarter financial results
November 8, 2022 | finance.yahoo.com
Ionis announces positive data from GSK's Phase 2b clinical study of bepirovirsen
November 8, 2022 | finance.yahoo.com
Is a Surprise Coming for Ionis (IONS) This Earnings Season?
November 7, 2022 | finance.yahoo.com
Ionis presents positive Phase 2 data in patients with IgA Nephropathy at American Society of Nephrology's Kidney Week 2022
November 4, 2022 | finance.yahoo.com
Ionis Regains Rights To Thrombosis Candidate From Bayer
November 4, 2022 | finance.yahoo.com
Ionis announces positive results from fesomersen development program
October 31, 2022 | americanbankingnews.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Rating of "Hold" by Analysts
October 27, 2022 | seekingalpha.com
IONS Ionis Pharmaceuticals, Inc.
October 26, 2022 | finance.yahoo.com
Ionis to hold third quarter 2022 financial results webcast
October 26, 2022 | finance.yahoo.com
Put Ionis Pharmaceuticals on Your Watchlist
October 12, 2022 | finance.yahoo.com
Ionis announces plan for new manufacturing facility in Oceanside, Calif.
September 27, 2022 | finance.yahoo.com
Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures
September 23, 2022 | finance.yahoo.com
Ionis' (IONS) Hypercholesterolemia Drug Not to Enter Phase III
See More Headlines
Receive IONS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

IONS Company Calendar

Last Earnings
11/03/2021
Today
12/06/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/23/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:IONS
CUSIP
46433010
CIK
874015
Web
www.ionispharma.com
Phone
(760) 931-9200
Fax
760-603-2700
Employees
660
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$46.80
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$26.00
Forecasted Upside/Downside
+23.1%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.12)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-28,600,000.00
Net Margins
0.91%
Pretax Margin
1.28%
Return on Equity
1.18%
Return on Assets
0.32%

Debt

Debt-to-Equity Ratio
2.10
Current Ratio
7.59
Quick Ratio
7.52

Sales & Book Value

Annual Sales
$810 million
Price / Sales
6.67
Cash Flow
$0.09 per share
Price / Cash Flow
428.28
Book Value
$5.47 per share
Price / Book
6.95

Miscellaneous

Outstanding Shares
142,050,000
Free Float
138,698,000
Market Cap
$5.40 billion
Optionable
Optionable
Beta
0.53

Key Executives

  • Dr. Brett P. Monia Ph.D. (Age 61)
    Founder, CEO & Director
    Comp: $1.32M
  • Ms. Elizabeth L. HougenMs. Elizabeth L. Hougen (Age 60)
    Exec. VP of Fin. & CFO
    Comp: $869.38k
  • Ms. Onaiza Cadoret-Manier (Age 57)
    Exec. VP, Chief Global Product Strategy & Operations Officer
    Comp: $755.52k
  • Mr. Patrick R. O'Neil Esq. (Age 48)
    Exec. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec.
    Comp: $815.69k
  • Dr. Stanley T. CrookeDr. Stanley T. Crooke (Age 77)
    Scientific Advisor
    Comp: $1.64M
  • Ms. B. Lynne Parshall Esq.Ms. B. Lynne Parshall Esq. (Age 68)
    J.D., Sr. Strategic Advisor & Director
    Comp: $701.77k
  • Dr. Eric E. Swayze Ph.D. (Age 56)
    Exec. VP of Research
    Comp: $739.3k
  • Mr. Joel Edwards (Age 61)
    VP of Corp. Operations
  • Mr. Darren Gonzales
    Chief Accounting Officer & Sr. VP
  • Dr. C. Frank Bennett (Age 65)
    Exec. VP & Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













IONS Stock - Frequently Asked Questions

Should I buy or sell Ionis Pharmaceuticals stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 2 sell ratings, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" IONS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
View IONS analyst ratings or view top-rated stocks.

What is Ionis Pharmaceuticals' stock price forecast for 2023?

9 brokerages have issued 1-year price objectives for Ionis Pharmaceuticals' shares. Their IONS share price forecasts range from $26.00 to $65.00. On average, they anticipate the company's stock price to reach $46.80 in the next twelve months. This suggests a possible upside of 22.2% from the stock's current price.
View analysts price targets for IONS or view top-rated stocks among Wall Street analysts.

How have IONS shares performed in 2022?

Ionis Pharmaceuticals' stock was trading at $30.43 at the beginning of the year. Since then, IONS stock has increased by 25.9% and is now trading at $38.31.
View the best growth stocks for 2022 here.

When is Ionis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our IONS earnings forecast.

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) issued its quarterly earnings data on Wednesday, November, 3rd. The company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by $0.05. The business earned $133 million during the quarter, compared to analysts' expectations of $162.01 million. Ionis Pharmaceuticals had a trailing twelve-month return on equity of 1.18% and a net margin of 0.91%. The company's revenue for the quarter was down 16.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.22) EPS.

What guidance has Ionis Pharmaceuticals issued on next quarter's earnings?

Ionis Pharmaceuticals updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $575.00M-, compared to the consensus revenue estimate of $594.45 million.

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.02%), Bellevue Group AG (6.66%), Price T Rowe Associates Inc. MD (3.38%), ARK Investment Management LLC (2.62%), BVF Inc. IL (2.02%) and Tweedy Browne Co LLC (1.92%). Insiders that own company stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $38.31.

How much money does Ionis Pharmaceuticals make?

Ionis Pharmaceuticals (NASDAQ:IONS) has a market capitalization of $5.44 billion and generates $810 million in revenue each year. The company earns $-28,600,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis.

How many employees does Ionis Pharmaceuticals have?

The company employs 660 workers across the globe.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The official website for the company is www.ionispharma.com. The company can be reached via phone at (760) 931-9200, via email at wwalke@ionisph.com, or via fax at 760-603-2700.

This page (NASDAQ:IONS) was last updated on 12/6/2022 by MarketBeat.com Staff